Answers are grounded in this paper and cite their sources.
Objectives: To create chimeric antigen receptor (CAR) T cells and evaluate the effect on CD19+ B cells in animal models of acute lymphoblastic leukemia. Methods: An experimental research (In vitro and In vivo) was conducted at the Department of Pathophysiology, Military Medical University, from June 2019 to 2022. Results: Successfully transformed and created CAR-T cells by nucleofection technology; the survival rate of cells after transformation was 48.9 - 60.7%. The expression of CAR molecules on the T cell surface after 21 and 28 days of culture were 66.23% and 97.34%, respectively. CAR-T cells could proliferate vigorously when co-cultured with cancer cells carrying CD19+, and the ability to lyse cancer cells carrying CD19+ after 6 and 24 hours (lysis efficiency was 24.8 - 71.8%, respectively); this ability increased with the proportion of CAR-T cells present in the medium and with the time of co-culture. CAR-T cell block restricted the proliferation of CD19+ cancer cells (through Luciferase activity), prolonged the survival time, and increased the survival rate of the murine model of acute lymphoblastic leukemia. Conclusion: CAR-T cells can grow when co-cultured with CD19 receptor-expressing cells and CD19+ cancer cell lysis. The excellent effect when using generated CAR-T cells to treat a mouse model of acute leukemia was assessed by Luciferase activity associated with CD19+ cancer cells, survival time, and mouse weight.
No takes yet. Share an insight, caveat, or question.
Hồ et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: